The approval is based on data from a Phase 3 trial, which involved 405 patients, according to an Oct. 29 news release from the agency. The study showed a major molecular response rate of 68% at 48 weeks for asciminib compared to 49% for standard tyrosine kinase inhibitors.
Common adverse reactions included musculoskeletal pain, rash and fatigue, the release said. The approval utilized the FDA’s Real-Time Oncology pilot program, streamlining the review process.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.